Study provides new insights into the genetic complexity of cancer metastasis
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Jul-2025 20:10 ET (8-Jul-2025 00:10 GMT/UTC)
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments. Importantly, the phase 3 trial’s rapid development and implementation, coupled with its successful enrollment of a group of patients broadly representative of the larger U.S. population, establish Pragmatica-Lung as a paradigm-shifting model for the design and conduct of future large randomized studies.
In a new multi-center study led by Boston University Chobanian & Avedisian School of Medicine, researchers have found that aggressive surgery in patients with advanced gallbladder cancer (T3/T4) can lead to high complication and mortality rates, especially in those in the T4 patients that invade adjacents organs of the disease.
Cancer cell movement during metastasis is a dynamic process regulated by several different signals. However, the way cells receive, process and respond to these signals has been extremely hard to detect, but is now made easier by a new visualisation tool.
AI tools can provide close to precise survival estimates of patients with prostate cancer, according to scientists
Scientists have identified why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and developed a new combination therapy. Identifying this mechanism is important as it identifies patients who will not respond to single agent ICB treatment such as anti-PD1 antibody therapy, but are most likely to benefit from the new combination therapy that they have identified, anti-CD30. By simply adding anti-CD30 for these patients, they believe they can improve response to cancer and avoid costly delays.
When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity.
A new study from researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.